- history of infection confirmed by sars-cov-2. - positive igg antibodies test for sars-cov-2 at the time of admission. - have received any dose of nitazoxanide within 7 days prior to screening. - known hypersensitivity to any of the study medication components. - use of any investigational or unregistered drug or vaccine within 30 days prior to screening, or use planned during the study period. - inability to comply with study procedures. - current breastfeeding. - pregnancy. - intolerance or inability to take oral medication. - history of severe liver disease (child-pugh b or c) and/or chronic kidney disease.

- history of infection confirmed by sars-cov-2. - positive igg antibodies test for sars-cov-2 at the time of admission. - have received any dose of nitazoxanide within 7 days prior to screening. - known hypersensitivity to any of the study medication components. - use of any investigational or unregistered drug or vaccine within 30 days prior to screening, or use planned during the study period. - inability to comply with study procedures. - current breastfeeding. - pregnancy. - intolerance or inability to take oral medication. - history of severe liver disease (child-pugh b or c) and/or chronic kidney disease.